BackEkso Bionics Holdings Overview

Ekso Bionics Holdings Total Revenue

Ekso Bionics Holdings's total revenue is $12M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$2.14M
36.56% YoY

As of Mar 2026

Annual Revenue (TTM)

$11.56M
34.08% YoY

Trailing 12 months ending Mar 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Ekso Bionics Holdings (EKSO) FAQ

Ekso Bionics Holdings posts a total revenue of $12M as of March 2026. That compares with $18M in the prior-year period — down 34.1% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Ekso Bionics Holdings's total revenue was $18M. The latest reading is $12M — a 34.1% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Ekso Bionics Holdings's $12M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Ekso Bionics Holdings's financial statement story. At $12M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EKSO's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Ekso Bionics Holdings's other metric pages and overview cover the third.